AC8 2.44% 40.0¢ auscann group holdings ltd

MC is already available to patients under the Special Access...

  1. 8,916 Posts.
    lightbulb Created with Sketch. 860
    MC is already available to patients under the Special Access Scheme for the treatment of pain in chronic conditions (such as cancer etc). Substantial clinical trials have already been undertaken overseas on MC use with numerous successful end points achieved.

    The science is not the issue here. It is the TGA approving products for their function and then permitting access to those products based on doctor requests. The sooner we have the finished final form product that delivers a stable and controlled dosage, the sooner product approval can be secured.

    Request approval for MC under the SAS has been growing fast. It's a boom medical field.

    A breakdown of the number of SAS Category B approvals by month for the previous 12 months, a 1800% increase or so YoY :

    Month Number of SAS Category B approvals
    1 February 2018 37
    2 March 2018 54
    3 April 2018 89
    4 May 2018 132
    5 June 2018 146
    6 July 2018 188
    7 August 2018 229
    8 September 2018 237
    9 October 2018 331
    10 November 2018 567
    11 December 2018 491
    12 January 2019 672
 
watchlist Created with Sketch. Add AC8 (ASX) to my watchlist
(20min delay)
Last
40.0¢
Change
-0.010(2.44%)
Mkt cap ! $126.7M
Open High Low Value Volume
41.5¢ 43.0¢ 40.0¢ $554.8K 1.349M

Buyers (Bids)

No. Vol. Price($)
2 3925 40.0¢
 

Sellers (Offers)

Price($) Vol. No.
40.5¢ 13217 3
View Market Depth
Last update - 16.10pm 24/04/2019 (20 minute delay) ?
(live)
Last
40.5¢
  Change
-0.010 ( 0.52 %)
Open High Low Volume
42.0¢ 43.0¢ 40.0¢ 158389
Last updated 15.54pm 24/04/2019 (live) ?
AC8 (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.